Lyra Therapeutics, INC. (LYRA) — 8-K Filings

8-K Filings (19)

• Lyra Therapeutics Terminates Material Agreement — Apr 17, 2026 Risk: medium
  Lyra Therapeutics, Inc. filed an 8-K on April 17, 2026, to report the termination of a material definitive agreement. The filing indicates that this termination
• Lyra Therapeutics Terminates Material Agreement — Apr 10, 2026 Risk: medium
  Lyra Therapeutics, Inc. filed an 8-K on April 10, 2026, to report the termination of a material definitive agreement. The filing does not specify the agreement
• Lyra Therapeutics Files 8-K — Sep 4, 2025 Risk: low
  Lyra Therapeutics, Inc. filed an 8-K on September 4, 2025, reporting other events and financial statements. The company, formerly known as Arsenal Medical, Inc.
• Lyra Therapeutics Faces Nasdaq Delisting Warning — Aug 22, 2025 Risk: high
  Lyra Therapeutics, Inc. announced on August 20, 2025, that it received a notification from Nasdaq regarding its failure to meet the minimum bid price requiremen
• Lyra Therapeutics Director Departs, Officer Compensation Noted — Aug 1, 2025 Risk: low
  Lyra Therapeutics, Inc. announced on August 1, 2025, the departure of Dr. David L. Brown from its Board of Directors. The company also reported on compensatory
• Lyra Therapeutics Announces Material Definitive Agreement — Jun 27, 2025 Risk: medium
  Lyra Therapeutics, Inc. announced on June 26, 2025, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales of equ
• Lyra Therapeutics Merges with HealthBeacon Subsidiary, Delists from Nasdaq — Jun 23, 2025 Risk: medium
  On June 13, 2025, Lyra Therapeutics, Inc. announced the closing of its previously disclosed merger with a subsidiary of HealthBeacon Ltd. The transaction was ap
• Lyra Therapeutics Files 8-K — Jun 9, 2025 Risk: low
  Lyra Therapeutics, Inc. filed an 8-K on June 9, 2025, reporting other events and financial statements. The company, formerly known as Arsenal Medical, Inc., is
• Lyra Therapeutics Files 8-K with Corporate Updates — Jun 2, 2025 Risk: low
  Lyra Therapeutics, Inc. filed an 8-K on May 27, 2025, reporting an amendment to its articles of incorporation, a Regulation FD disclosure, and other events. The
• AtriCure to Acquire Lyra Therapeutics for $1.1B — May 19, 2025 Risk: medium
  Lyra Therapeutics, Inc. announced on May 14, 2025, that it has entered into a definitive agreement to be acquired by AtriCure, Inc. for approximately $1.1 billi
• Lyra Therapeutics Files 8-K — Jan 10, 2025 Risk: low
  Lyra Therapeutics, Inc. filed an 8-K on January 10, 2025, to report current information. The filing primarily concerns financial statements and exhibits, as wel
• Lyra Therapeutics Appoints New Directors, Adjusts Executive Pay — Dec 13, 2024 Risk: medium
  Lyra Therapeutics, Inc. announced on December 12, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company ele
• Lyra Therapeutics Faces Nasdaq Delisting Notice — Jul 23, 2024 Risk: high
  Lyra Therapeutics, Inc. announced on July 19, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The com
• Lyra Therapeutics Files 8-K with Corporate Updates — Jun 18, 2024 Risk: low
  Lyra Therapeutics, Inc. filed an 8-K on June 18, 2024, reporting events that occurred on June 13, 2024. The filing indicates changes to the company's articles o
• Lyra Therapeutics Directors Depart, Costs Disclosed — May 21, 2024 Risk: medium
  Lyra Therapeutics, Inc. announced on May 16, 2024, the departure of two directors, Dr. David Epstein and Dr. Robert Langer, effective immediately. The company a
• Lyra Therapeutics Appoints New CMO, Director — Apr 19, 2024 Risk: medium
  Lyra Therapeutics, Inc. announced on April 15, 2024, the appointment of Dr. Jeffrey L. Meckler as Chief Medical Officer and the election of Ms. Jennifer M. McNe
• Lyra Therapeutics Files 8-K on Financials — Mar 21, 2024 Risk: low
  On March 21, 2024, Lyra Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as we
• Lyra Therapeutics Appoints New Chief Medical Officer — Mar 1, 2024 Risk: low
  Lyra Therapeutics, Inc. announced the appointment of Dr. Marc D. G. de Beer as Chief Medical Officer, effective February 26, 2024. Dr. de Beer brings extensive
• Lyra Therapeutics Files Routine 8-K, Confirms Nasdaq Listing — Jan 8, 2024
  Lyra Therapeutics, Inc. filed an 8-K on January 8, 2024, to disclose general corporate information and confirm its registration on The Nasdaq Global Market unde

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX